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Purpose: To analyze the difference in the prediction accuracy with an active surveillance (AS) protocol between two eras 
(pre-International Society of Urological Pathology [pre-ISUP]-2014 vs. post-ISUP2014).
Materials and Methods: We retrospectively analyzed 118 candidates for AS who underwent radical prostatectomy between 
2009 and 2017. We divided our patients into two groups (group 1 [n=57], operation date 2009–2015; group 2 [n=61], op-
eration date 2016–2017). Pathologic slides in group 1 were reviewed to distinguish men with cribriform pattern (CP) because 
the determination of Gleason scores in old era had been based on pre-ISUP2014 classification. Postoperative outcomes in 
the two eras were analyzed twice: first, all men in group 1 vs. group 2; second, the remaining men after excluding those with 
CPs in group 1 vs. group 2.
Results: The proportion of men with insignificant prostate cancer (iPCa) was significantly lower in group 1 than in group 2 
(36.8% vs. 57.4%, p=0.040). After excluding 11 men with CPs from group 1, those remaining (46 men) were compared 
again with group 2. In this analysis, the proportion of men with iPCa was similar between the two groups (old vs. contempo-
rary era: 41.3% vs. 57.4%, p=0.146). Nine of 11 men with CP had violated the criteria for iPCa in the earlier comparison.
Conclusions: The accuracy of the AS protocol has been affected by the coexistence of CPs and pure Gleason 6 tumors in the 
pre-ISUP2014 era. We suggest to use only contemporary (post-ISUP2014) data to analyze the accuracy with AS protocols in 
future studies.
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INTRODUCTION
Active surveillance (AS) is a management strategy in 
a superselect group of low-risk prostate cancer patients, 
involving close monitoring of the course of disease with 
the expectation to intervene if the cancer progresses. 
The goal of AS is to minimize overtreatment for indo-
lent disease, and to defer treatment and its potential 
adverse effects. Currently, several AS criteria have 
been proposed [1-5].
However, the risk of AS has also been highlighted 
because there have been reports on adverse features in 
radical prostatectomy (RP) specimens from men who 
initially fulfilled the preoperative AS criteria. Such 
misclassification results in the possibility of missing an 
opportunity for cure, or the progression or metastasis 
of the cancer before treatment. Ploussard et al [6] re-
ported that the rate of upgrading of Gleason score (GS) 
and pathological upstaging was up to 42% in patients 
who were initially considered to have insignificant 
prostate cancer according to Epstein criteria. Lee et al 
[7] reported that even the most stringent AS criteria 
were not able to fully discriminate low-risk patients 
from those affected by clinically significant prostate 
cancer. In an effort to reduce such misclassification, the 
use of other modalities such as multiparametric mag-
netic resonance imaging (mpMRI) in combination with 
the AS protocol is currently being investigated. Al-
though mpMRI might be a promising tool for selecting 
AS candidates, some limitations remain with regard to 
its sensitivity and specificity [8-16]. 
In the 2014 consensus meeting, the International So-
ciety of Urological Pathology (ISUP) assigned Gleason 
pattern 4 to all cribriform patterns (CPs), based on the 
findings that any CP in prostate cancer is associated 
with a less favorable outcome, such as extraprostatic 
extension (EPE) and positive surgical margin (PSM) 
[17-19]. These changes resulted in a grade shift, in 
that many cases that used to be graded GS 6 are now 
graded GS 7. Consequently, the current GS 6 cases 
(so-called ‘pure’ GS 6 in the post-2014 ISUP era) are a 
homogeneous group of tumors lacking CPs and have 
a less aggressive nature, in contrast to GS 6 tumors of 
the original GS system era (pre-2014 ISUP era).
Accordingly, we hypothesised that the accuracy for 
predicting insignificant prostate cancer with the AS 
protocol can be different according to the study era. As 
there is a paucity of studies on this issue at present, 
we aimed to analyze the difference in the prediction 




This study was approved by the Institutional Ethics 
Committee of Yonsei University College of Medicine 
after reviewing the study protocol and procedures (Reg. 
No. 4-2018-1111). The requirement for written consent 
was waived because of the retrospective nature of the 
study. The data were anonymized before the analysis.
2. Demographics and clinicopathological 
data
A total of 675 consecutive patients with localized or 
locally advanced prostate cancer treated with RP at 
Yonsei Severance Hospital between 2009 and 2017 were 
selected. Of these individuals, patients with incomplete 
medical records were excluded. Patients who had pre-
operative androgen deprivation or radiation therapy 
were also excluded. With respect to the number of total 
biopsy cores, we excluded men who did not undergo a 
12-core biopsy. This resulted in a study population of 
637 men.
We used the Prostate Cancer Research International: 
Active Surveillance (PRIAS) protocol to select candi-
dates for AS, because this protocol is the most appro-
priate for Asian patients with prostate cancer among 
five Western protocols (Johns Hopkins Medical Institu-
tions [1], Memorial Sloan-Kettering Cancer Center [2], 
University of California at San Francisco [3], PRIAS 
[4], and University of Miami [5]), according to several 
authors [20,21]. The PRIAS protocol consists of GS 6 or 
less on biopsy, clinical stage T2 or less, prostate specific 
antigen (PSA) 10 ng/mL or less, PSA density (PSAD) 0.2 
ng/mL/cm3 or less and no more than 2 positive cores. 
On the basis of these criteria, we identified a total of 
118 candidates for AS. We divided these patients into 
two groups according to the date of operation: group 
1 (n=57, operation date 2009–2015, old era) and group 
2 (n=61, operation date 2016–2017, contemporary era), 
because the modified GS system (released in the 2014 
ISUP consensus meeting) has been applied at Yonsei 
Severance Hospital since 2016.
We obtained data on patient demographics and 
clinical characteristics, including age, prostate volume 
https://doi.org/10.5534/wjmh.200037
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on transrectal ultrasound, preoperative PSA values, 
PSAD, number of positive biopsy cores, clinical/patho-
logical T stage, biopsy/pathological GS, and pathological 
tumor volume.
For clinical staging, all patients underwent prostate 
MRI using a 3.0-T MRI system (Intera Achieva 3.0 T; 
Phillips Medical System, Latham, NY, USA) at 3–4 
weeks after prostate biopsy and before surgery. MRI 
included T2-weighted, diffusion-weighted, and dynamic 
contrast-enhanced imaging. T2-weighted images were 
acquired in three orthogonal planes (axial, sagittal, and 
coronal). From the diffusion-weighted imaging data, 
the apparent diffusion coefficient map was generated, 
with b values of 0 and 1,000 s/mm2, by using the mono-
exponential model. All mpMRIs were reviewed using 
the Prostate Imaging Reporting and Data System (PI-
RADS) ver. 2.
All RP specimens were weighed, inked, fixed over-
night in ambient formalin, cut at 3 mm intervals, and 
submitted as quadrants. To determine tumor volume in 
each nodule, slides were photocopied in a background 
of 1 mm2 grid, and the amount of mm2 in each tumor 
nodule was manually counted. To convert square into 
cubic millimeters, the total number of mm2 was multi-
plied by 3 (thickness of prostate tissue sections) and 1.12 
(fixation shrinkage factor). The nodule with the high-
est GS or the largest nodule (if nodules were the same 
grade) was considered dominant. All the processing was 
performed by an experienced genitourinary patholo-
gist (NHC). Insignificant prostate cancer was defined 
as organ-confined, GS 6 disease with a dominant tumor 
nodule volume of <0.5 cm3 [22].
3. Study endpoint
The main objective of this study was to compare the 
accuracy of the AS protocol for predicting insignificant 
prostate cancer, when data from the old era vs. the con-
temporary era were applied. A flow diagram illustrat-
ing our study design is shown in Fig. 1.
4. Reviewing the Gleason scores of patients 
in the old (pre-International Society of 
Urological Pathology-2014) era
Because the determination of GSs in group 1 had 
been based on the pre-ISUP2014 classification system, 
we needed to recheck all pathological slides in group 
1 to determine which patient had or did not have any 
CPs in their biopsy pathologies (G 3+3=6 tumors that 
were determined in the pre-ISUP2014 era). This evalu-
ation was also performed by NHC. The diagnostic ac-
curacy (sensitivity and specificity) of identifying CPs 
was identical between the two study eras by the same 
pathologist (NHC).
5. Statistical analyses
The patients’ preoperative and pathological charac-
teristics were calculated using means for continuous 















Analysis of the proportion of
insignificant prostate cancer at RP
118 Patients met the protocol
675 Patients underwent radical prostatectomy
(January 2009 December 2017)
PRIAS protocol
(1) Biopsy GS 6 or less
(2) Clinical stage T2 or less
(3) PSA 10 ng/mL or less
(4) PSAD 0.2 ng/mL/cm or less
(5) No more than 2 positive biopsy cores
3
Fig. 1. Flow diagram illustrating study 
design. PRIAS: Prostate Cancer Research 
International: Active Surveillance, GS: 
Gleason score, PSA: prostate specific 
antigen, PSAD: prostate specific antigen 
density, ISUP: International Society of 
Urological Pathology, RP: radical prosta-
tectomy, CP: cribriform pattern.  
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Student’s t-test and Mann–Whitney–Wilcoxon test 
were used for continuous variables, and the chi-square 
test and Fisher’s exact test were used to compare 
categorical variables between groups. Multivariate 
logistic regression models that included all collected 
variables were constructed to identify the predictors of 
insignificant prostate cancer. Statistical analyses were 
performed with R statistics ver. 3.5.1. Values of p<0.05 
were considered to indicate statistical significance.
RESULTS
Table 1 summarizes the baseline patient character-
istics. There were no significant differences in preop-
erative PSA value, prostate volume, PSAD, number 
of positive biopsy cores, and distribution of clinical 
T stages between the two groups. Age was higher in 
group 2 (61.9±14.8 years vs. 66.7±11.3 years, p=0.001).
Postoperatively, the proportion of insignificant pros-
Table 2. Postoperative histopathological outcomes in the 2 groups
Variable Group 1 (pre-ISUP2014 era; n=57) Group 2 (post-ISUP2014 era; n=61) p-value
Pathologic stage 0.114a
   pT2 42 (73.7) 53 (86.9)
   pT3 15 (26.3) 8 (13.1)
Postoperative Gleason score 0.459b
   6 37 (64.9) 42 (68.9)
   7 18 (31.6) 19 (31.2)
   8–10 2 (3.5) 0 (0)
Tumor volume (cm3) 1.16±0.11 0.73±0.11 0.003c
Organ confined Gleason score 6 disease 30 (52.6) 38 (62.3) 0.381a
Insignificant prostate cancer 21 (36.8) 35 (57.4) 0.040a
Values are presented as number (%) or mean±standard deviation. 
ISUP: International Society of Urological Pathology.
aCalculated using chi-square test. 
bCalculated using Fisher’s exact test.
cCalculated using Student’s t-test.
Table 1. Preoperative patient characteristics
Characteristic Group 1 (pre-ISUP2014 era; n=57) Group 2 (post-ISUP2014 era; n=61) p-value
Age (y) 61.9±14.8 66.7±11.3 0.001a
PSA (ng/mL) 5.20±0.28 4.98±0.07 0.486a
Prostate volume (cm3) 39.9±10.5 40.5±2.6 0.830a
PSAD (ng/mL/cm3) 0.14±0.03 0.13±0.02 0.227a
Positive biopsy cores (n) 1.24±0.0 1.40±0.0 0.068a
Clinical T stage 0.681b
   cT1c 21 (36.9) 18 (29.5)
   cT2a/b 30 (52.6) 35 (57.4)
   cT2c 6 (10.5) 8 (13.1)
PI-RADS v2 0.586c
   1–2 12 (21.0) 19 (31.1)
   3 16 (28.1) 17 (27.9)
   4 23 (40.4) 21 (34.4)
   5 6 (10.5) 4 (6.6)
Values are presented as mean±standard deviation or number (%). 
ISUP: International Society of Urological Pathology, PSA: prostate specific antigen, PSAD: prostate specific antigen density, PI-RADS: prostate im-
aging reporting and data system.
aCalculated using Student’s t-test or Mann–Whitney–Wilcoxon test. 
bCalculated using chi-square test. 
cCalculated using Fisher’s exact test.
https://doi.org/10.5534/wjmh.200037
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tate cancer was 47.4% (56/118) in the overall cohort. 
Table 2 shows the postoperative histopathological out-
comes for each group. The proportion of pT3 was 26.3% 
and 13.1% in group 1 and group 2, respectively (p=0.114). 
The distribution of postoperative GSs was similar be-
tween the two groups. The pathological tumor volume 
was higher in group 1 (1.16±0.11 cm3 vs. 0.73±0.11 cm3, 
p=0.003). The proportion of insignificant prostate can-
cer was significantly lower in group 1 than in group 2 
(36.8% vs. 57.4%, p=0.040). Multivariate logistic regres-
sion analysis revealed the predictors of insignificant 
prostate cancer (Table 3). The study era was found to 
be an independent predictor of meeting the criteria for 
insignificant prostate cancer (odds ratio 3.01, 95% confi-
dence interval 1.30–6.97, p=0.010).
We then rechecked all pathological slides in group 1 
to distinguish patients harbouring CPs in their biopsy 
specimen. When we reviewed a total of 57 pathologies 
in group 1, 11 patients (19.3%) had CP in their preoper-
ative biopsy specimens. After we excluded these 11 men 
from group 1, the remaining men (46 patients) were 
compared again with group 2 for their histopathologi-
cal outcomes (Table 4). In this analysis, there was no 
statistically significant difference in the proportion of 
insignificant prostate cancer between the two groups 
(old vs. contemporary era: 41.3% vs. 57.4%, p=0.146).
The analysis of men having CPs showed that 9 of 
the 11 patients had violated the criteria for insignifi-
cant prostate cancer in our earlier comparison (57 vs. 61 
men). Table 5 shows the reasons for incorrect assign-
ment to AS in the 11 patients.
Table 3. Multivariate logistic regression analysis of the prediction of 
insignificant prostate cancer
Variable Odds ratio 95% CI p-value
Age 0.95 0.89–1.01 0.076
Prostate volume 1.03 1.00–1.06 0.079
PSA 0.84 0.63–1.12 0.239
Clinical T stage
   cT1c – – 0.558
   cT2a/b 0.91 0.39–2.11
   cT2c 1.00 0.27–3.79
Study era
   Pre-ISUP2014 – – 0.010
   Post-ISUP2014 3.01 1.30–6.97
CI: confidence interval, PSA: prostate specific antigen, ISUP: Interna-
tional Society of Urological Pathology.
Table 4. Postoperative histopathological outcomes in the 2 groups (after excluding 11 patients with cribriform pattern in group 1)
Variable Group 1 (pre-ISUP2014 era; n=46) Group 2 (post-ISUP2014 era; n=61) p-value
Pathologic stage 0.233a
   pT2 35 (76.1) 53 (86.9)
   pT3 11 (23.9) 8 (13.1)
Postoperative Gleason score 0.341b
   6 31 (67.4) 42 (68.9)
   7 13 (28.3) 19 (31.2)
   8–10 2 (4.3) 0 (0)
Insignificant prostate cancer 19 (41.3) 35 (57.4) 0.146a
Values are presented as number (%). 
ISUP: International Society of Urological Pathology.
aCalculated using chi-square test. 
bCalculated using Fisher’s exact test.
Table 5. Reasons for incorrect assignment to active surveillance in 11 











Patient 1 + + +
Patient 2 + - +
Patient 3 - + +
Patient 4 + - +
Patient 5 - - +
Patient 6 - + +
Patient 7 + + +
Patient 8 - - +
Patient 9 + - +
Patient 10  
   (no violation)
- - -
Patient 11  
   (no violation)
- - -
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DISCUSSION
The risk of AS has been highlighted because adverse 
features have been reported in RP specimens from 
men who were initially considered as having insignifi-
cant prostate cancer. Because of such misclassification, 
AS involves the possibility of missing an opportunity 
for cure, the possibility of progression or metastasis of 
the cancer before treatment, increased anxiety of living 
with untreated cancer, the need to undergo frequent 
examinations and prostate biopsies, and other disad-
vantages.
Despite recent efforts to improve the predicting 
power of AS (e.g., by using a combination of mpMRI 
and the AS protocol), there are still limitations with 
respect to the accuracy. The UK National Institute for 
Health and Care Excellence is the first national body 
to recommend the use of MRI in men considering AS 
[8]. Tay et al [9] reported that combining mpMRI with 
the National Comprehensive Cancer Network low-risk 
clinical criteria resulted in a statistically significant 
improvement in specificity. Similarly, Schoots et al [10] 
reported that mpMRI at the beginning of AS can de-
tect significant prostate cancer in 30% to 50% of men. 
However, although mpMRI is a promising tool, there 
are limitations that should be considered and not all 
studies have demonstrated a clear diagnostic benefit 
with mpMRI. For example, Mertan et al [12] reported 
that mpMRI during AS candidate selection has a rela-
tively low specificity, especially in association with PI-
RADS scores of 3 and 4. Concerning the false-negative 
results, Borofsky et al [13] reported that a small pro-
portion of clinically important cancers can be missed 
or their size can be underestimated, depending on the 
quality of the scan and its interpretation. In one study, 
it was estimated that the negative predictive value of 
mpMRI considerably varies from 0.65 to 0.94 [14]. Simi-
larly, as described in the 2018 European Association of 
Urology guidelines, the prostate cancer detection rate 
with mpMRI was reported to be rather low in GS 6 
cancers and small lesions (<0.5 cm3) [15] in contrast to 
GS ≥7 cancers [16].
Accordingly, a limitation still exists concerning the 
accuracy for selecting the proper AS candidates despite 
recent attempts with the use of mpMRI. Under these 
circumstances, we paid attention to the modified 2014 
ISUP grading system. A major point of divergence 
from the original GS system is with the assignment 
of grade 4 to all CPs. Such modification was based on 
the recent findings that any cribriform morphology 
in prostate cancer is associated with a less favorable 
outcome. In 2011, it was reported that both large and 
small cribriform glands in RP specimens were associ-
ated with biochemical failure (BCF) [23]. In 2013, Dong 
et al [24] also demonstrated that the presence of a CP 
was an independent predictor for both BCF and metas-
tasis after RP. In 2014, a series of articles showed CP to 
be associated with EPE, PSM, BCF, distant metastases, 
and disease-specific death [25,26]. In the 2014 ISUP 
consensus meeting in Chicago, 100% of the participants 
agreed that CPs should be assigned to Gleason pattern 
4, regardless of morphology.
Therefore, a possible explanation may be that a cer-
tain proportion of men who were found to have GS 
3+3=6 cancer in the pre-ISUP2014 era had harboured 
unfavorable features such as CPs, and this could be 
an important factor in the incorrect assignment to AS. 
That is, we hypothesised that prediction accuracy with 
an AS protocol could be different under the contempo-
rary GS system even if the same AS protocol is used.
In the comparison of groups 1 and 2 (Table 2) in our 
earlier analysis, the accuracy for predicting insignifi-
cant prostate cancer was lower in group 1 (p=0.040). 
However, the analysis after excluding patients with CP 
from group 1 showed a similar prediction accuracy be-
tween the two groups (p=0.146; Table 4). These findings 
indicate that the accuracy of the AS protocol for pre-
dicting insignificant prostate cancer has been affected 
by the coexistence of CPs and pure GS 6 tumors in the 
pre-ISUP2014 era.
In our analysis, 81.8% (9/11) of men with CPs had 
violated the criteria for insignificant prostate cancer. 
Seven of the nine patients had harboured at least two 
reasons among three (GS upgrading, T upstaging, and 
tumor volume >0.5 cm3) for incorrect assignment to AS 
(Table 5). These findings are in line with a previous 
study [26] that highlighted an association of the CP 
with EPE. In their study, EPE was observed in 28.2% of 
GS 6 cases with CP and in 1.7% of GS 6 cases without 
CP. Also, the association between CP and the presence 
of concurrent high-grade carcinoma was demonstrated. 
Undoubtedly, we believe that the high likelihood of 
having concurrent EPE or high-grade tumor with CP 
had led to the inaccuracy of the AS protocol.
Although several recent studies [11,12,27,28] had 
evaluated the role of mpMRI in reducing the incor-
https://doi.org/10.5534/wjmh.200037
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rect assignment to AS or the cancer detection rate 
with mpMRI, no study has compared data from the 
pre-ISUP2014 era with those from the post-ISUP2014 
era. Yim et al [28] studied only pre-ISUP2014 data 
(2006–2013), and Mertan et al [12] analyzed only post-
ISUP2014 data (May 2015–September 2015). Luzzago 
et al [11] (2012–2016 data) and Fan et al [27] (2009–2018 
data) enrolled mixed data from both periods.
Regarding the prediction accuracy of Epstein criteria 
under updated GS system, there were several reports 
on such issue although most of them analyzed data 
from pre-2005 vs. post-2005 ISUP system. For example, 
Kryvenko et al [29] studied whether the Epstein crite-
ria could still be valid under the use of updated 2005 
GS system, analyzing the patients who underwent RP 
from 2004 to 2012. The authors demonstrated that the 
Epstein criteria (either original [22] or modified [29]) 
maintained its accuracy. As an earlier report, Albertsen 
et al [30] referred the improved clinical outcome solely 
as a result of GS reclassification, despite the lack of an 
actual biologic change (so called Will Rogers phenom-
enon).
However, our study represents the first description of 
a comparison of pre-2014 and post-2014 ISUP era data 
with respect to the accuracy of the AS protocol. Our 
results suggest that we need to use only contemporary 
data to analyze the prediction accuracy with AS proto-
cols in future studies. That is to say, we need to use the 
data only from patients after 2014, or patients whose 
GS determination was based on 2014 ISUP system, 
because it is possible that the adoption of 2014 ISUP 
change did not happen uniformly and instantaneously 
either depending on institutions. Moreover, such stan-
dardization (the use of only post-2014 data) will be im-
portant for a more precise determination of the role of 
mpMRI in AS.
This study has several limitations. First, the number 
of patients was relatively small. Given the low statisti-
cal power of this study, further multicentric studies 
with more patients are needed to confirm our findings. 
Second, the retrospective nature also limit this study. 
Third, the proportions of patients with CPs would be 
rather variable among numerous previous studies on 
the AS protocols (in pre-ISUP2014 era); however, this 
does not diminish our conclusion. The proportion was 
about 19% (11/57) in the present study. Because it is 
possible that some old-era studies included a higher 
proportion of such patients than in the present study, 
the results from those studies inevitably have less reli-
ability.
CONCLUSIONS
Our analysis demonstrated that the accuracy of the 
AS protocol for predicting insignificant prostate can-
cer has been affected by the coexistence of CPs and 
pure Gleason 6 tumors in the pre-ISUP2014 era. In 
future studies, we need to use only contemporary (post-
ISUP2014) data when analyzing the prediction accu-
racy with AS protocols.
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